###### Key messages

What is already known on this subject?
======================================

To date, none of the available mechanical circulatory support devices significantly improves 30-day mortality in patients with cardiogenic shock due to acute myocardial infarction.

What does this study add?
=========================

Impella improves parameters of shock severity but is associated with higher bleeding complications and has no significant effect on 30-day mortality compared with the use of IABP.

How might this impact on clinical practice?
===========================================

The benefit of Impella on mortality should be evaluated in an adequately powered randomised controlled trial.

Introduction {#s1}
============

Acute myocardial infarction complicated by cardiogenic shock (AMICS) remains an important cause of death, despite early percutaneous coronary revascularisation.[@R1] Recent data show that in these patients, in-hospital mortality reaches 66% and long-term mortality 80%.[@R2]

In patients with AMICS, the intra-aortic balloon pump (IABP) was used for mechanical support for decades, but it was downgraded from the guideline recommendations after the IABP-SHOCK II trial failed to show any mortality benefit over medical therapy alone.[@R3] Impella (Abiomed, Danvers, Massachusetts, USA) is a promising alternative for percutaneous mechanical circulatory support (pMCS) that has been utilised as a bridge to recovery. It consists of a miniaturised axial flow pump fitted onto a pigtail catheter, pumping blood from the left ventricle into the ascending aorta and providing a cardiac output of 2.5 L/min (Impella 2.5) and up to 4.0 L/min (Impella CP).[@R5] It actively unloads the left ventricle reducing the stroke-work and myocardial oxygen consumption, thereby providing cardioprotection and robust haemodynamic support.[@R7]

Two randomised controlled trials (RCT) and a metanalysis of RCTs investigated the benefit of Impella versus IABP, but they were highly underpowered to detect a mortality difference.[@R10] Moreover, as noted from the investigators of those trials, RCTs in the setting of AMICS are extremely difficult to conduct. Therefore, the profile of patients who may profit from support with Impella still remains unclear.

The aim of our study was to investigate the effect of Impella compared with IABP in patients with AMICS in terms of improvement of parameters of shock severity and all-cause mortality at 30 days.

Methods {#s2}
=======

Study design and data collection {#s2-1}
--------------------------------

This retrospective study included patients with AMICS, who were treated with either Impella or IABP, from a historical cohort of two tertiary cardiovascular centres of the Charité-University Medicine in Berlin. Patients treated between January 2011 and March 2017 were included in the study. Data at baseline and at 30-day follow-up were collected from a computerised patient information system (*COPRA Systems, Germany*). The local ethics committee approved data collection. The results of the study are reported in accordance with the Strengthening the Reporting of Observational Studies in Epidemiology guidelines.[@R13]

Inclusion and exclusion criteria {#s2-2}
--------------------------------

### Inclusion {#s2-2-1}

Patients with AMICS due to ST-segment elevation myocardial infarction (STEMI) or non-STEMI (NSTEMI), with symptom onset within 24 hours of clinical presentation, were included. The shock was defined by the need for continuous administration of vasopressors for \>30 min in order to maintain a systolic blood pressure of \>90 mm Hg, despite adequate fluid loading, evidence of end-organ hypoperfusion, clinical or radiological signs of pulmonary congestion and lactate serum concentration at clinical presentation \>20 mg/dL.[@R4]

### Exclusion {#s2-2-2}

Exclusion criteria were: contraindication for device implantation, resuscitation lasting \>30 min, presence of left ventricular thrombus, presence of a mechanical aortic valve, severe aortic valve stenosis, severe peripheral arterial disease precluding placement of Impella, significant right heart failure, presence of an atrial or ventricular septal defect including postinfarction ventricular septal defect, left ventricular rupture and cardiac tamponade. [Online supplementary file 1](#SP1){ref-type="supplementary-material"} depicts the patient selection process.
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Interventional and device therapy {#s2-3}
---------------------------------

The characteristics of IABP and Impella are described elsewhere.[@R14] Operators were experienced in the use of both devices. Patients with AMICS underwent primary percutaneous coronary intervention (PCI) of the culprit lesion in accordance with current local guidelines.[@R15] In presence of multivessel disease, the modality of revascularisation, that is, immediate versus staged PCI of the non-culprit lesion(s), was left to the discretion of the operator. Duration of mechanical support was guided by the treating intensive care physician. Weaning was achieved by a stepwise reduction of the amount of support provided by the pMCS device. In 2013, following the publication of the IABP-SHOCK II trial, the use of IABP was terminated and replaced by Impella.

Outcomes {#s2-4}
--------

The primary outcome was all-cause mortality at 30 days. Other outcomes were adverse cardiac events during hospitalisation, such as myocardial infarction (MI), target vessel revascularisation (TVR), stroke, and changes in parameters of shock severity (ie, improvement of cardiac power index (CPI), left ventricular ejection fraction (LVEF), serum lactate levels, and Simplified Acute Physiology Score II (SAPS II)), reduction in the ICU stay and duration of device therapy. The recently published IABP-SHOCK II score, a short-term mortality risk score, derived from patients included in the IABP-SHOCK II trial,[@R17] was calculated in each patient, allowing the exploration of Impella effect on outcomes in each risk subcategory. The inotropic score and CPI were calculated over the first 5 days, as previously described.[@R18] LVEF was measured at admission, at the time of device weaning and at discharge by transthoracic echocardiography. Pre-PCI time interval was defined as the time interval from symptom onset to the first PCI balloon inflation. The pre-device time interval was defined as the time interval from symptom onset to device implantation. The bleeding complications were classified according to the Bleeding Academic Research Consortium (BARC) classification.[@R19]

Statistical analysis {#s2-5}
--------------------

Data are expressed as medians with interquartile ranges (IQR) or frequencies and percentages, as appropriate. Normality of distribution was testes with the Shapiro-Wilk test. Wilcoxon rank sum for was used for comparisons of non-parametric variables and the Χ² test for categorical variables. Changes within the first 5 days for parameters of shock severity (CPI, inotropic score, lactate and SAPS II) and from baseline to discharge for LVEF were analysed using a generalised linear-mixed model considering the between and within-patient differences. Kaplan-Meier analysis estimated the cumulative incidence of mortality at 30 days. Cox-regression analysis was performed to identify independent predictors of 30-day mortality while adjusting for potential confounding variables (IABP-SHOCK II risk score and cardiopulmonary resuscitation (CPR)). To assess the validity of the Cox proportional hazard model, the proportional assumption hazard was tested based on Schoenfeld residuals. All probability values were two-tailed and considered significant for p\<0.05. Data analysis was performed using STATA V.14.0 statistical software.

Results {#s3}
=======

Baseline and procedural characteristics {#s3-1}
---------------------------------------

Out of 116 included patients, 62 (53%) received Impella and 54 (47%) IABP. [Table 1](#T1){ref-type="table"} outlines the baseline characteristics of all patients and according to the device received. The median age in the entire cohort was 72 years (IQR, 64--77) and 73% were men. Demographic characteristics and cardiovascular risk factors were similarly distributed among groups, except for the history of smoking, significantly more frequent in the IABP group. STEMI was the most frequent index event in both groups (Impella vs IABP: 68% vs 74%; p=0.54). No significant differences regarding comorbidities, rate of out of or in-hospital CPR or the type of index event (ie, NSTEMI and STEMI) were observed. At the time of index event, 50% of patients presented in sinus rhythm, 22% in ventricular fibrillation and 11% in supraventricular arrhythmia ([online supplementary file 1](#SP1){ref-type="supplementary-material"}). Overall, no significant difference in the rate of different types of cardiac rhythm was observed. The baseline estimated short-term mortality risk, calculated using the IABP-SHOCK II score, was comparable among groups ([table 2](#T2){ref-type="table"}). The periprocedural characteristics are outlined in [table 3](#T3){ref-type="table"}. At baseline, patients treated with Impella had significantly worse LVEF (28 \[20-35\] vs 34 \[30-39\] %; p=0.01), and comparable SAPS II and serum lactate levels (60 \[32-95\] vs 49 \[23-77\] mg/dL; p=0.09). The size of MI was significantly higher in patients receiving Impella (CK-max 2822 \[887--6355\] vs 1330 \[473--4626\] U/L; p=0.04). There was no significant difference in the rate of device implantations before stenting (55% vs 54%; p=1.00), time to device implantation (144 vs 121 min; p=0.17) and postinterventional TIMI III flow rates (77% vs 60%, p=0.07) in patients treated with Impella versus IABP.

###### 

Baseline characteristics

  ------------------------------------------------------------------------------
                                Total\       IABP\        Impella\     P value
                                (N=116)      (N=54)       (N=62)       
  ----------------------------- ------------ ------------ ------------ ---------
  Age, years                    72(64--77)   71(64--75)   73(62--79)   1.00

  Male                          85 (73)      41 (76)      44 (71)      0.67

  BMI                           26(24--29)   26(24--29)   26(25--29)   0.63

  Smoke                         29 (25)      19 (35)      10 (16)      0.02

  Hypertension                  70 (60)      34 (63)      36 (58)      0.70

  Hyperlipidaemia               74 (64)      38 (70)      36 (58)      0.18

  NIDDM                         52 (45)      20 (37)      32 (51)      0.11

  Previous stroke               7 (6.0)      3 (3.7)      5 (8.1)      0.44

  Peripheral artery disease     5 (4.3)      3 (5.6)      2 (3.2)      0.66

  Previous MI                   18 (16)      7 (13)       11 (18)      0.61

  Previous PCI                  22 (19)      7 (13)       15 (24)      0.15

  One-vessel CAD                18 (16)      7 (13)       11 (18)      0.35

  Two-vessel CAD                27 (23)      12 (22)      15 (24)      0.35

  Three-vessel CAD              68 (59)      35 (65)      33 (53)      0.35

  CABG                          3 (2.6)      0 (0)        3 (4.9)      0.24

  Pre-existing cardiomyopathy   6 (5.2)      3 (5.5)      1 (1.6)      0.45

  Pacemaker/CRT                 5 (4.3)      1 (1.8)      4 (6.5)      0.37

  CKD                           20 (17)      8 (15)       12 (19)      0.62

  **CPR**                       70 (60)      32 (59)      38 (61)      0.45

   In hospital CPR              38 (54)      21 (66)      17 (45)      0.10

   Out of hospital CPR          32 (46)      11(34)       21 (55)      0.10

  Index event AMI                                                      

   STEMI                        82 (71)      40 (74)      42 (68)      0.54

   NSTEMI                       34 (29)      14 (26)      20 (32)      0.45
  ------------------------------------------------------------------------------

Data depicted as median (IQR) or counts (%). P values are from Wilcoxon rank sum test or Fischer test.

AMI, acute myocardial infarction; BMI, body mass index; CABG, coronaryartery bypass graft; CAD, coronary artery disease; CKD, chronic kidney disease; CPR, cardiopulmonary resuscitation; CRP, C reactive protein; CRT, cardiac resynchronization therapy; IABP-SHOCK II, Intra-aortic Balloon Pump in Cardiogenic Shock II; LDH, lactate dehydrogenase; MI, myocardial infarction; NIDDM, non-insulin-dependent diabetes mellitus; PCI, percutaneous coronary intervention; Pre-PCI time, time from symptom onset to the first PCI balloon inflation; Pre-device time, time from symptom onset to device implantation.

###### 

IABP-SHOCK II risk score

  --------------------------------------------------------------
  Score                 Total\    IABP\     Impella\   P value
                        (N=116)   (N=54)    (N=62)     
  --------------------- --------- --------- ---------- ---------
  Low (0--2)            40 (36)   17 (34)   23 (38)    0.68

  Intermediate (3--4)   50 (45)   23 (46)   27 (44)    0.85

  High (5--9)           21 (19)   10 (20)   11 (18)    0.79
  --------------------------------------------------------------

Data depicted as counts (%). P values are from the Fischer test. Data on the IABP-SHOCK II risk score was notretrievable for five patients.

IABP-SHOCK II, Intra-aortic Balloon Pump in Cardiogenic Shock II.

###### 

Periprocedural characteristics

  ----------------------------------------------------------------------------------------
                                        IABP\                Impella\            P value
                                        (N=54)               (N=62)              
  ------------------------------------- -------------------- ------------------- ---------
  LVEF                                  34(30-39)            28(20-35)           0.01

  SAPS II                               60(48-74)            68(47-79)           0.16

  Lactate, mg/dL                        49(23-77)            60(32-95)           0.09

  Creatinine, mg/dL                     1.37 (1.08--1.89)    1.39 (1.14--1.75)   0.93

  pH                                    7.22 (7.12--7.36)    7.25 (7.12--7.35)   0.59

  Haemoglobin, g/dL                     13.7 (11.8--14.6)    13.5 (12.1--14.3)   0.86

  Glucose, mg/dL                        302 (226--407)       340 (261--429)      0.18

  CK-max., U/L                          1330 (\[473--4626)   2822 (887--6355)    0.04

  CK-MB max., U/L                       221 (68--544)        336 (109--680)      0.19

  Pre-PCI time, min                     121 (60--196)        111 (71--262)       0.42

  Pre-device time, min                  121 (82--228)        144(107--364)       0.17

  Device implantation before stenting   29 (54)              34 (55)             1.00

  TIMI flow at baseline                                                          

   TIMI 0                               34 (63)              41 (66)             0.85

   TIMI I                               12 (22)              17 (27)             0.17

   TIMI II                              8 (15)               4 (6.5)             0.22

  TIMI III flow after primary PCI\*     31 (60)              47 (77)             0.07
  ----------------------------------------------------------------------------------------

Data depicted as median (IQR) or counts (%). P values are from Wilcoxon rank sum test or Fischer test.

\*Data on TIMI III flow after PCI were not retrievable for two patients in the IABP and one patient in the Impella group.

CK-MB, Creatine kinase isoform MB; CK-max, maximal creatine kinase; CPR, cardiopulmonary resuscitation; LVEF, left ventricular ejection fraction; SAPS II, Simplified Acute Physiology Score II; TIMI, thrombolysis in myocardial infarction.

Characteristics during hospitalisation {#s3-2}
--------------------------------------

Clinical and procedural characteristics during the stay at the intensive care unit (ICU) are summarised in [table 4](#T4){ref-type="table"}. Overall, \>90% of patients in both groups were mechanically ventilated for a median of 24 and 36 hours in the Impella and IABP group, respectively. In each group, 39% of patients received renal replacement therapy (RRT). The median duration of pMCS was 24 (12-36) hours in both groups, and more than half of were successfully weaned from each device (60% and 55%, Impella vs IABP, respectively). No significant difference regarding the duration of mechanical ventilation, RRT, ICU stay and rate of device-triggered arrhythmias was observed. Although the use of catecholamines at admission and during the ICU stay was initially high for both devices, significantly faster weaning within the first 4 days was achieved in patients treated with Impella ([figure 1A](#F1){ref-type="fig"}) However, the overall increase of CPI was not significantly different between the two groups ([online supplementary file 1](#SP1){ref-type="supplementary-material"}). Compared with patients treated with IABP, those treated with Impella displayed a significant reduction of lactate levels and SAPS II within the first 4 days after device implantation ([figure 1B, C](#F1){ref-type="fig"}). Moreover, following Impella treatment, LVEF improved significantly from baseline to discharge ([figure 1D](#F1){ref-type="fig"}).

![Changes in clinical parameters and use of catecholamines during hospitalisation (A) inotropic score, B) serum lactate levels and (C) SAPS II from baseline to the fourth day after device implantation, and (D) LVEF from baseline to discharge are depicted. measurements are presented as median and 25th--75th percentile. P values are from a generalised linear model considering the between and within difference among groups. The catecholamine dose was evaluated by the inotropic score (µ/kg/min.)=dopamine+dobutamine +100\*epinephrine +100\*norepinephrine +100\*isoproterenol. IABP, intra-aortic balloon pump; LVEF, left ventricular ejection fraction; SAPS II, Simplified Acute Physiology Score II.](openhrt-2018-000987f01){#F1}

###### 

Clinical and procedural characteristics at the ICU

  ---------------------------------------------------------------------------------
                                              IABP\         Impella\      P value
                                              (N=54)        (N=62)        
  ------------------------------------------- ------------- ------------- ---------
  Mechanical ventilation                      51 (94)       60 (96)       0.66

  Duration of mechanical ventilation, hours   36(12--168)   24(12--216)   0.73

  Renal replacement therapy                   21 (39)       24 (39)       1.00

  Duration of dialysis, hours                 48(24--84)    36(12--240)   0.95

  Duration of device therapy, hours           24(12--36)    24(12--36)    0.74

  Days of ICU stay                            3(1--11)      3.5(1--18)    0.57

  Successful weaning                          30 (55)       36 (60)       0.70

  Arrhythmias during device-therapy           17 (32)       17 (27)       0.68

   Supraventricular tachycardia               7 (13)        7 (11)        0.78

   Ventricular tachycardia                    4 (7.4)       6 (9.7)       0.75

   Ventricular fibrillation                   5 (9.2)       2 (3.2)       0.24

   Bradycardia                                2 (3.7)       3 (4.8)       1.00
  ---------------------------------------------------------------------------------

Data depicted as median \[IQR\] or counts (%). P values are from Wilcoxon rank sum or Fischer's test.

IABP, intra-aortic balloon pump; ICU, intensive care unit.

Feasibility and safety {#s3-3}
----------------------

Both devices were successfully implanted in all patients. The balloon size of the IABP was 40 cm^3^. An Impella 2.5 was implanted in 19 (31%) and an Impella CP in 43 (69%) patients. The complications occurring from the time of device implantation until discharge are summarised in [table 5](#T5){ref-type="table"}. Rates of stroke, MI and TVR were similar in both groups (Impella vs IABP: 1.6% vs 1.8, p=1.00; 1.6% vs 5.5%, p=0.48% and 3.2% vs 0%, p=0.43). No significant differences in the rate of pericardial effusion (1.6% vs 5.5%, p=0.33) or cardiac tamponade requiring intervention (3.2% vs 3.7%, p=1.00) were observed. Furthermore, rates of bleeding BARC 2 and 3, (14.5% vs 7.4%, p=0.25) and limb ischaemia (8% vs 0%, p=0.06) were similar among the device groups but showed a strong trend of higher frequency in Impella-treated patients. Moreover, the number of transfused erythrocytes concentrates due to bleeding complications was significantly higher following the Impella placement (4 vs 3 units, p=0.03).

###### 

Complications

  ------------------------------------------------------
                          IABP\     Impella\   P value
                          (N=54)    (N=62)     
  ----------------------- --------- ---------- ---------
  Stroke                  1 (1.8)   1 (1.6)    1.00

  MI                      3 (5.5)   1 (1.6)    0.48

  TVR                     0 (0)     2 (3.2)    0.43

  Pericardial effusion    3 (5.5)   1 (1.6)    0.33

  Pericardial tamponade   2 (3.7)   2 (3.2)    1.00

  Limb ischaemia          0 (0)     5 (8.0)    0.06

  Bleeding BARC 2 and 3   4 (7.4)   9 (14.5)   0.25

  Number of RBCs          3(2-4)    4(4-7)     0.03

  Number of FFPs          4(2-6)    2(2-7)     0.60
  ------------------------------------------------------

Data depicted as median (IQR) or counts (%). P-values are from Wilcoxon rank sum or Fischer test.

BARC 2, Bleeding Academic Research Consortium type 2; BARC 3, Bleeding Academic Research Consortium type 3; FFP, fresh frozen plasma; MI, myocardial infarction; RBC, red blood concentrate; TVR, target vessel revascularisation.

Outcomes at 30 days {#s3-4}
-------------------

Mortality at 30 days and detailed causes of death are depicted in the [online supplementary file 1](#SP1){ref-type="supplementary-material"}. Overall, all-cause mortality was 59%, with no significant differences between the Impella and IABP group (52% and 67%, p=0.13). The most frequent cause of death in both groups was heart failure from AMICS (43%). Notably, numerically fewer patients died of heart failure from AMICS in the Impella-treated group (36% and 52%, p=0.09; [online supplementary file 1](#SP1){ref-type="supplementary-material"}). Other causes of death were multiorgan failure due to systemic inflammatory response syndrome (SIRS, Impella 11% and IABP 5.5%-; p=0.33), and palliation from irreversible postanoxic brain damage (4.8% and 9.3%, p=0.47). Overall, 6.9% of patients underwent palliation for irreversible postanoxic brain damage with no significant differences among the treatment groups (4.8% and 9.3%, p=0.47). In a subgroup analysis, after excluding deaths from palliation due to postanoxic brain damage, 30-day mortality due to heart failure from AMICS, did not reach statistical significance in Impella-treated patients (37% and 57%, p=0.05, [online supplementary file 1](#SP1){ref-type="supplementary-material"}. In Kaplan-Meier analysis, all-cause mortality did not differ between the two treatment groups, regardless of whether patients undergoing palliation were (p=0.13, [figure 2A](#F2){ref-type="fig"}) or were not (p=0.23, [figure 2B](#F2){ref-type="fig"}) included in the analysis. After stratification according to the baseline estimated IABP-SHOCK II risk score, no survival benefit of Impella was observed in either subgroup ([figure 2C, D](#F2){ref-type="fig"}).

![Kaplan-Meier estimates of all-cause mortality at 30 days. Depicted are the Kaplan-Meier estimates of all-cause mortality at 30 days. P-values from the log-rank test. events were analysed (A) in the whole study population, (B) after excluding deaths due to palliation by irreversible postanoxic brain damage, (C) in the low-intermediate and (D) high IABP-SHOCK II risk score subgroup. IABP-SHOCK II, Intra-aortic Balloon Pump in Cardiogenic Shock II.](openhrt-2018-000987f02){#F2}

Independent predictors of 30-day mortality {#s3-5}
------------------------------------------

In multivariate analysis, treatment with Impella showed no significant effect on mortality (HR 0.82, 95% CI 0.50 to 1.36; p=0.45). Previous CPR (HR 3.22, 95% CI 1.76 to 5.89; p\<0.01) and estimated, intermediate (HR 2.77, 95% CI 1.42 to 5.40; p\<0.01) and high (HR 4.32 95% CI 2.03 to 9.24; p=0.01) IABP-SHOCK II risk score, considerably increased the risk of mortality ([figure 3A](#F3){ref-type="fig"}). In the subgroup of patients with estimated low-intermediate risk, no significant effect on mortality after treatment with Impella was observed (HR 0.59, 95% CI 0.34 to 1.04; p=0.07; [figure 3B](#F3){ref-type="fig"}).

![Independent predictors of all-cause mortality at 30 days. (HRs are from COX regressions with 95% CIs). Events were analysed (A) in the whole study population and (B) in the subgroup of patientswith low-intermediate IABP-SHOCK II score. adjustment covariates including IABP-SHOCK II risk score and CPR. CPR, cardiopulmonary resuscitation; IABP-SHOCK II, Intra-aortic Balloon Pump in Cardiogenic Shock II.](openhrt-2018-000987f03){#F3}

Discussion {#s4}
==========

To our knowledge, this is one of the largest historical cohorts investigating the benefit of haemodynamic support with Impella versus IABP in patients with severe AMICS.

The following findings emerged from our study. First, compared with IABP, treatment with Impella significantly improves parameters of shock severity and LVEF. Second, at 30 days, there is no significant benefit in all-cause mortality compared with IABP. Third, there is no significant increase in rates of stroke, reinfarction and TVR but treatment with Impella was associated with a significantly higher number of transfused erythrocytes concentrates due to bleeding complications.

AMICS is a complex disease, still associated with a mortality of 40%--75% despite early revascularisation.[@R20] Impella has been frequently used in this clinical setting due to its feasibility and safety in emergency conditions and the benefits of ventricular unloading, supported from preclinical and clinical data.[@R7] Superior haemodynamic support provided by Impella explains the significant reduction of lactate levels and SAPS II and the lower inotropic scores observed in our study. However, the CPI, length of ICU stay, the rate of mechanical ventilation and that of RRT were not different from patients treated with IABP. The onset of multiorgan failure due to SIRS, occurring in 11% of patients receiving Impella versus 5.5% of those receiving IABP, might have obscured the beneficial effects provided by the latter. The results of our study are in line with those of the Impella versus Intra-Aortic Balloon Pump in Cardiogenic Shock trial, a metanalysis of existing RCTs, and a recent multicentre retrospective registry, all demonstrating the lack of benefit of Impella in reducing 30 day mortality.[@R11] [@R22] These studies included patients presenting in different stages of shock severity, while to date, the profile of patients with AMICS who may profit from pMCS remains still unclear. In fact, a benefit in terms of reduction in 30-day mortality with Impella, as compared with standard medical therapy or IABP, has not been shown in any clinical setting and for any pMCS for that matter. AMICS is indeed a condition with broad severity of presentation. Approximately 50% of patients survive AMICS without pMCS,[@R4] on the contrary, pMCS might be futile in others because of the advanced state of disease. Therefore, an accurate risk stratification early in this emergency setting can help guide further clinical decision and refine patient selection towards achieving a real benefit from pMCS devices. Previous studies suggested a protective effect exerted by Impella in 'lower risk' patients.[@R24] According to the results of the recently published 'Detroit Cardiogenic Shock Initiative', the rapid delivery of Impella was beneficial in patients presenting in a still responsive shock stage. The authors implemented a regional protocol based on rapid early delivery of pMCS within 90 min of shock onset and early discontinuation of inotropic and vasopressors, being able to show an improvement of mortality compared with institutional historical cohorts.[@R24] In our study, we did not find a significant difference in 30-day mortality after stratifying the patients according to the IABP-SHOCK II risk score. In fact, the estimated mortality rate in the low-intermediate risk group was approximately 60%--70%, reflecting the bailout character of Impella use in these patients with poor a haemodynamic profile. Although in the Detroit study the cohort was highly preselected, the results of the study indicate that in 'lower-risk' patients, the benefits of early pMCS implantation merit further investigation in appropriately powered trials.

In patients with high IABP-SHOCK II risk score, support with Impella is clearly futile. In this clinical setting, it was recently shown that the combination of Impella and venoarterial extracorporeal membrane oxygenation (VA-ECMO) provides a more robust haemodynamic support and is superior to VA-ECMO alone.[@R18]

The present study has several limitations. First, due to the nature of the retrospective design, comprehending patients from a historical cohort, residual confounding cannot be excluded even after multivariable adjustments. Second, despite being considerable compared with other studies, the size of our cohort was insufficient to detect significant differences in mortality. Finally, despite applying strict criteria for patient selection, there was some degree of heterogeneity, probably due to the lack of evidence in the use of pMCS devices.

In conclusion, the debate on Impella is still ongoing, in a scenario where, the mortality benefit of any available percutaneous device has still to be proven in an RCT. Due to the difficulty of conducting trials in this emergency setting, data from observational studies are important and should serve at least as hypothesis generating. In this large retrospective study, we observed that haemodynamic support with Impella is feasible and improves the parameters of shock severity compared with former standard IABP. Impella does not improve 30-day mortality, however, a possible benefit in selected patients with lower estimated mortality risk should be investigated in adequately powered RCTs.

Data depicted as median (IQR) or counts (%). P values are from Wilcoxon rank sum or Fischer's test. AMI-acute myocardial infarction, BMI-Body Mass Index, CABG-coronary artery bypass graft, CAD-coronary artery disease, CKD-chronic kidney disease, CPR-cardiopulmonary resuscitation, CRP-C-reactive Protein, CRT-cardiac resynchronization therapy, IABP-SHOCK II- short-term mortality risk score, LDH-Lactate Dehydrogenase, MI-myocardial infarction NIDDM**-**non-insulin dependent diabetes mellitus, PCI-percutaneous coronary angioplasty, Pre-PCI time-time from symptom onset to the first PCI balloon inflation, Pre-device time-time from symptom onset to device implantation.

Data depicted as counts (%). P values are from Fischer's test. IABP-SHOCK II-Intra-aortic Balloon Pump in Cardiogenic Shock II. Data on the IABP Shock II risk score was not retrievable for five patients.

Data depicted as median (IQR) or counts (%). P values are from Wilcoxon rank sum or Fischer's test. CK-max.-maximal Creatine-Kinase, CK-MB-Creatine-Kinase Isoform MB, CPR-cardiopulmonary resuscitation, LVEF-left ventricular ejection fraction (%), TIMI-Thrombolysis in Myocardial Infarction. SAPS II-Simplified Acute Physiology Score II. \* Data on TIMI III flow after PCI was not retrievable for two patients in the IABP and one patient in the Impella group.

Data depicted as median (IQR) or counts (%). P values are from Wilcoxon rank sum or Fischer's test. ICU- Intensive care unit.

Data depicted as median (IQR) or counts (%). P values are from Wilcoxon rank sum or Fischer's test. BARC 2 and 3-Bleeding Academic Research Consortium type 2 and 3, FFP-Fresh Frozen Plasma, MI-myocardial infarction, RBC-Red Blood Concentrate, TVR-target vessel revascularisation.
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